The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results